Features
A New Era for Wet AMD Trials
Peer-Reviewed
Understanding trial design, statistical outcomes, and evolving FDA requirements is increasingly important as new therapies aim to demonstrate meaningful differences from established anti-VEGF treatments.
By Lejla Vajzovic, MD, FASRS, Arshad M. Khanani, MD, MA, FASRS, Jeffrey S. Heier, MD
What I Learned Starting an Independent Retina Practice
Lessons from my first year going solo.
By Paul Hahn, MD, PhD
Year One of Building a Research Program
Growing a clinical trials program in a private retina practice in East Texas—the opportunities, the constraints, and what I would tell a practice considering starting one.
By Samuel Minaker, MD, MSc
The Retina OR Bottleneck
Surgical economics limit operating room access and create barriers to vitreoretinal surgery.
By Deanna Ingrassia Miano, DO, MS, Miguel A. Busquets, MD, FACS, FASRS
Incorporating AI Into Clinical Trial Operations
AI agents could help sponsors, CROs, and research sites manage complexity, improve efficiency, and reduce administrative burden.
By Namrata Saroj, OD, Mark R. Barakat, MD, Ram Yalamanchili
HELIOS-3: Investigating Axpaxli for Diabetic Retinopathy
Peter K. Kaiser, MD, FASRS, discusses the phase 3 HELIOS-3 trial of AXPAXLI for diabetic retinopathy, which is enrolling patients in Argentina, the United States, and other countries.
By Patricio G. Schlottmann, MD, Peter K. Kaiser, MD
Rethinking Epiretinal Membrane Disease
At SARyV 2026, Andrea Govetto, MD, PhD, discusses why epiretinal membrane disease should be understood as more than a disorder of the retinal surface.
By Patricio G. Schlottmann, MD, Andrea Govetto, MD, PhD
SARyV 2026: Highlights From Ushuaia
Martín Charles, MD, and Patricio G. Schlottmann, MD, reflect on the scientific discussions, international participation, and clinical insights shared at the meeting in Ushuaia.
By Martín Charles, MD, Patricio G. Schlottmann, MD
How the Modern Light Environment Contributes to Myopia
At SARyV 2026 in Ushuaia, Argentina, Francine Behar-Cohen, MD, PhD, examined the effects of artificial lighting, reduced outdoor exposure, and circadian rhythms on ocular growth.
By Jim Gallagher, content director, Vision
Light, Screens, and the Risk of Myopia
Francine Behar-Cohen, MD, PhD, discusses how modern lighting affects eye development and what can be done to reduce children's exposure to artificial light.
By Patricio G. Schlottmann, MD, Francine Behar-Cohen, MD, PhD
New Prospects for Gene Therapy in IRDs
Aaron Nagiel, MD, PhD, reflects on advances in retinal gene therapy since Luxturna's approval and the prospect of additional treatments.
By Patricio G. Schlottmann, MD, Aaron Nagiel, MD, PhD
Imaging and AI in Retinal Clinical Trials
Yijun Huang, PhD, and David P. Bingaman, DVM, PhD, DACVO, discuss the role of centralized imaging services in ophthalmology trials and review new AI-based endpoints for AMD and GA.
By Yijun Huang, PhD, David P. Bingaman, DVM, PhD, DACVO, Patricio G. Schlottmann, MD
New Insights Into EMAP and Its Relationship to AMD
New research raises questions about the classification of extensive macular atrophy with pseudodrusen-like appearance and its potential implications for interpreting geographic atrophy clinical trial results.
By Alessandro Feo, MD, Patricio G. Schlottmann, MD
Argentina Streamlines Clinical Trial Approval Procedures
At SARyV 2026, Guillermo Cardozo reviewed increasing ophthalmology trial activity, revisions to approval procedures, and challenges facing research centers.
By Jim Gallagher, content director, Vision
Gene Therapy for IRDs: Real-World Lessons and New Directions
Aaron Nagiel, MD, PhD, discusses long-term experience with Luxturna and early clinical findings from Opus Genetics’s OPGx-BEST1 program at SARyV 2026.
By Aaron Nagiel, MD, PhD
Web Exclusives
Beyond Surgery: The Methotrexate Debate
Controversies in Care
Does methotrexate improve surgical outcomes in PVR? Retina specialists examine the benefits, limitations, and unanswered questions surrounding its use for prophylaxis.
By Michael Colucciello, MD, Vivienne Hau, MD, PhD, John B. Miller, MD, et al.
Future-Proofing Your Practice
New technologies could help retina specialists manage growing patient volumes while maintaining quality of care.
By Deepak Sambhara, MD, FASRS
Departments
Building for the Future
Upfront
The November/December issue has a focus on practice management and clinical trials.
By Diana V. Do, MD
You Didn’t Add a Study, You Interrupted a Workflow
Practice Management Strategies
Why clinical trials require retina practices to rethink staffing, scheduling, communication, and patient flow.
By Elizabeth Cifers, MBA, MSW, CHC, CPC
Clinical Trial Update November 2026
Access Retinal Physician's listing of all active clinical trials in AMD, DME, RVO, and uveitis.
Supported Content
Comanagement Strategies in GA Care: Building a Collaborative Care Model for Geographic Atrophy
Referral is not the end of primary eye care
By Damon Dierker, OD, FAAO, Ankur M. Shah, MD, FASRS